Track the latest insights on zidovudine price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.

Get real-time access to monthly/quarterly/yearly prices Request Sample
During the second quarter of 2026, zidovudine prices in the USA reached 716,239 USD/MT in June. The market experienced upward price movement due to firm demand from pharmaceutical manufacturers and continued procurement activity for antiretroviral medicines. Supply conditions remained balanced, but production expenses related to pharmaceutical grade raw materials and quality control requirements supported higher pricing. Manufacturers focused on maintaining reliable output due to strict regulatory standards, which influenced cost structures.
During the second quarter of 2026, zidovudine prices in China reached 586,592 USD/MT in June. Prices increased due to steady export demand and controlled production availability among domestic manufacturers. Producers faced pressure from raw material procurement costs and compliance requirements associated with pharmaceutical manufacturing. The market remained supported by continued demand from international buyers seeking reliable active pharmaceutical ingredient supplies.
During the second quarter of 2026, zidovudine prices in Germany reached 674,849 USD/MT in June. The market recorded a gradual price increase as pharmaceutical companies maintained consistent purchasing activity. Higher manufacturing expenses, strict regulatory compliance requirements, and quality assurance processes contributed to pricing pressure. European suppliers continued to focus on dependable supply chains to meet pharmaceutical sector requirements.
During the second quarter of 2026, zidovudine prices in Netherlands reached 716,964 USD/MT in June. Prices moved upward due to stable pharmaceutical demand and strong supplier focus on maintaining premium quality standards. The market benefited from established pharmaceutical infrastructure and continued procurement from healthcare related industries. Production costs, regulatory requirements, and supply chain management expenses influenced pricing levels.
During the second quarter of 2026, zidovudine prices in Japan reached 670,442 USD/MT in June. The market observed price growth due to steady demand from pharmaceutical manufacturers and continued emphasis on high purity active pharmaceutical ingredients. Domestic suppliers managed production carefully due to strict quality standards and manufacturing requirements. Rising operational expenses and raw material cost pressures influenced pricing decisions.
During the fourth quarter of 2025, the zidovudine prices in the USA reached 663,561 USD/MT in December. Prices increased, supported by steady procurement from antiretroviral formulation manufacturers and structured government-backed supply programs. Additionally, regulated distribution frameworks and consistent API production scheduling influenced domestic availability across pharmaceutical channels.
During the fourth quarter of 2025, the zidovudine prices in China reached 557,915 USD/MT in December. Prices rose, driven by active export demand and stable production runs across bulk API facilities. Integrated raw material sourcing and disciplined capacity utilization shaped supply positioning within the global generic drug supply chain.
During the fourth quarter of 2025, the zidovudine prices in Germany reached 643,664 USD/MT in December. Prices moved upward, influenced by structured procurement from hospital and institutional healthcare systems. Controlled inventory management and compliance-driven production standards shaped transactional activity within the regulated pharmaceutical environment.
During the fourth quarter of 2025, the zidovudine prices in the Netherlands reached 677,450 USD/MT in December. Prices increased, supported by firm demand from pharmaceutical distributors and coordinated import flows within the European generic drug market. Centralized warehousing and regional redistribution networks influenced supply conditions.
During the fourth quarter of 2025, the zidovudine prices in Japan reached 614,532 USD/MT in December. Prices edged higher, reflecting stable procurement from domestic pharmaceutical companies and structured supply contracts. Strict regulatory oversight and quality compliance requirements shaped market availability.
During the third quarter of 2025, the zidovudine prices in the USA reached 637,365 USD/MT in September. Prices increased, supported by sustained demand from antiretroviral drug formulators and stable institutional procurement programs. Coordinated production scheduling and distributor inventory alignment influenced domestic supply dynamics.
During the third quarter of 2025, the zidovudine prices in China reached 542,244 USD/MT in September. Prices declined, influenced by moderated export orders and balanced API production levels. Structured raw material sourcing and sufficient plant operating rates shaped availability across bulk pharmaceutical markets.
During the third quarter of 2025, the zidovudine prices in Germany reached 623,584 USD/MT in September. Prices moved lower, reflecting cautious purchasing from pharmaceutical distributors and structured inventory adjustments within hospital supply chains. Regulated pricing mechanisms and balanced domestic production influenced transactional conditions.
During the third quarter of 2025, the zidovudine prices in the Netherlands reached 648,588 USD/MT in September. Prices decreased, supported by moderated import demand and calibrated distributor inventories within the European pharmaceutical trade network. Controlled procurement cycles shaped supply positioning.
During the third quarter of 2025, the zidovudine prices in Japan reached 582,219 USD/MT in September. Prices declined, influenced by steady but measured procurement from domestic pharmaceutical manufacturers and regulated supply contracts. Structured production planning shaped availability across healthcare channels.
During the second quarter of 2025, the zidovudine prices in the USA reached 619,463 USD/MT in June. Zidovudine prices in the USA during this quarter were influenced by fluctuations in the cost of key intermediates imported from Asia. The pharmaceutical manufacturing sector experienced margin pressures due to rising energy and compliance costs. Demand from federal procurement programs remained steady, while distribution expenses increased amid limited container availability and labor-related delays in warehousing and last-mile logistics.
During the second quarter of 2025, zidovudine prices in China reached 554,612 USD/MT in June. In China, zidovudine prices were shaped by shifts in active pharmaceutical ingredient (API) production capacity due to environmental compliance inspections across Zhejiang and Jiangsu provinces. Feedstock costs increased amid higher solvent prices and energy tariffs. Export-oriented supply was affected by congestion at major ports, while demand from the domestic healthcare sector remained consistent due to public health initiatives.
During the second quarter of 2025, the zidovudine prices in Germany reached 639,246 USD/MT in June. Zidovudine pricing in Germany was impacted by elevated input costs driven by energy market volatility and imported API expenses. Production was constrained by disruptions in the supply of pharmaceutical-grade raw materials from non-EU sources. The healthcare sector’s procurement cycles remained stable, but regulatory adjustments in drug pricing frameworks introduced uncertainty in forecasting and inventory planning across distribution networks.
During the second quarter of 2025, the zidovudine prices in the Netherlands reached 671,208 USD/MT in June. In the Netherlands, zidovudine prices in this quarter were affected by supply chain interruptions linked to delayed shipments of Indian and Chinese APIs. The pharmaceutical sector encountered higher manufacturing overheads due to rising labor and utility costs. Demand from public hospitals and clinics remained unchanged, but parallel trade activity increased, influencing regional supply balances and purchase prices.
During the second quarter of 2025, the zidovudine prices in Japan reached 593,435 USD/MT in June. Japan’s zidovudine pricing was influenced by increased import costs of raw materials from China and India, coupled with currency depreciation against major trading currencies. The pharmaceutical sector faced tighter production margins due to high regulatory compliance costs and elevated utility tariffs. Demand from the national healthcare system remained steady, while port delays and domestic freight rate increases further affected distribution costs.
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes zidovudine price trends, price forecast, and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing zidovudine prices.
Q2 2026:
The zidovudine price index in Europe showed a firm pricing trend supported by stable pharmaceutical demand and regulated supply conditions. Germany and Netherlands experienced upward movement due to higher production expenses, quality control requirements, and continued demand from healthcare manufacturers. European pharmaceutical companies maintained consistent procurement activity as suppliers focused on dependable delivery and compliance with strict manufacturing standards. Raw material availability remained a key factor influencing market sentiment, while producers managed output carefully to maintain product quality. The region continued to benefit from established pharmaceutical infrastructure and strong demand for active pharmaceutical ingredients.
Q4 2025:
As per the zidovudine price index, European prices moved upward, influenced by structured procurement from national healthcare systems and coordinated distribution across regulated pharmaceutical networks. Centralized warehousing in Western Europe and compliance-driven manufacturing standards shaped supply positioning. Demand from hospital formularies and government-backed treatment programs influenced transactional activity across the region’s generic antiretroviral market.
Q3 2025:
European prices moved downward, supported by moderated distributor restocking and structured inventory calibration within regulated pharmaceutical channels. Controlled import flows and balanced domestic API sourcing influenced supply conditions. Procurement remained aligned with scheduled healthcare program requirements rather than expanded stocking cycles.
Q2 2025:
As per the zidovudine price index, zidovudine prices in Europe during Q2 2025 were influenced by persistent supply disruptions of active pharmaceutical ingredients imported from Asia. The pharmaceutical manufacturing sector faced elevated production costs due to increased energy tariffs and strict regulatory compliance expenses. Delays in customs clearance and tighter parallel trade regulations further impacted regional supply flows. Stable demand from national healthcare systems sustained consistent procurement activity across member states.
This analysis can be extended to include detailed zidovudine price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
Q2 2026:
The zidovudine price index in North America reflected upward pricing pressure due to stable pharmaceutical consumption and higher manufacturing expenses. The USA market recorded price growth as suppliers managed production costs related to raw materials, regulatory compliance, and quality assurance activities. Demand from healthcare companies remained supportive, encouraging continued procurement activity. Pharmaceutical manufacturers focused on maintaining reliable supply networks and meeting strict product specifications. Inventory management strategies among buyers and suppliers influenced market conditions as companies balanced availability with cost control. The regional market remained stable, supported by ongoing demand for antiretroviral treatments and consistent pharmaceutical manufacturing activity.
Q4 2025:
As per the zidovudine price index, prices in North America increased, driven by sustained institutional demand and structured supply agreements within the antiretroviral therapy segment. Stable API manufacturing output and compliance-focused production standards supported predictable availability. Distribution networks aligned shipments with public health program timelines.
Q3 2025:
Prices in North America moved upward, influenced by continued demand from pharmaceutical formulators and steady government procurement programs. Integrated domestic production and controlled inventory management shaped market conditions across the regulated healthcare framework.
Q2 2025:
As per the zidovudine price index, in North America, zidovudine pricing was driven by fluctuations in import costs of key raw materials, particularly from Asia. The pharmaceutical sector experienced rising overheads linked to energy prices and labor constraints. Federal healthcare procurement schedules remained consistent, but distribution bottlenecks, including rail and trucking delays, affected delivery timelines. Additionally, inventory buildup strategies added temporary strain on short-term supply chains.
Specific zidovudine historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
Q2 2026:
The study includes zidovudine price trends across the Middle East and Africa, taking into consideration variables that have a direct impact on market prices, such as regional industrial expansion, natural resource availability, and geopolitical conflicts.
Q4 2025:
As per zidovudine price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
Q3 2025:
The report explores the zidovudine pricing trends and zidovudine price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
Q2 2025:
As per the zidovudine price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences. A tight supply from refineries, exacerbated by maintenance rounds and unplanned outages, put pressure on prices. Simultaneously, demand from the agrochemical sector during the planting season contributed to price changes.
In addition to region-wise data, information on zidovudine prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Q2 2026:
The Asia Pacific zidovudine market recorded moderate price growth, supported by pharmaceutical manufacturing activity and export demand. China and Japan experienced upward pricing trends due to higher production expenses and continued focus on quality standards. Regional manufacturers managed supply carefully to maintain consistent availability and meet international requirements. Demand from pharmaceutical companies remained stable, supported by ongoing healthcare applications. Raw material procurement conditions and manufacturing efficiency influenced supplier pricing decisions. The region continued to remain an important production base for active pharmaceutical ingredients, with market participants closely monitoring supply conditions and buyer requirements.
Q4 2025:
Across Asia Pacific, zidovudine prices moved upward, supported by firm export demand from bulk API manufacturing hubs and steady procurement from domestic pharmaceutical formulation companies. Production facilities in major manufacturing centers maintained disciplined operating rates, while regulated quality compliance standards ensured controlled output volumes. Structured export scheduling to regulated markets influenced shipment timing, and integrated raw material sourcing supported predictable production continuity. Additionally, procurement activity remained aligned with institutional healthcare demand and government-backed antiretroviral treatment programs, shaping transactional flows across the region’s pharmaceutical supply chain.
Q3 2025:
Zidovudine prices moved downward overall, influenced by moderated export orders and calibrated procurement from domestic pharmaceutical manufacturers. Bulk API producers maintained balanced operating rates, while structured inventory adjustments across distribution networks shaped availability within regulated healthcare channels. Controlled raw material sourcing and stable production scheduling ensured consistent supply, though purchasing remained measured in response to scheduled treatment program requirements rather than expanded stocking activity.
Q2 2025:
Zidovudine prices in the Asia Pacific region were shaped by environmental compliance inspections across major production zones in China and India, which limited API output. The pharmaceutical manufacturing sector experienced higher input costs due to energy price adjustments and rising solvent rates. Regional demand from public health programs remained firm, while port congestion and intra-regional shipping delays added logistical challenges to supply continuity.
This zidovudine price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Q2 2026:
Latin America's zidovudine market is heavily influenced by its abundant natural resources, particularly in Chile and Brazil. However, political uncertainty and varied regulatory regimes can cause significant volatility in zidovudine prices.
Q4 2025:
Latin America's zidovudine market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in zidovudine prices.
Q3 2025:
Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting Latin America’s ability to meet international demand consistently. Moreover, the zidovudine price index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing zidovudine pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
IMARC's latest publication, “Zidovudine Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2026 Edition,” offers a comprehensive examination of the zidovudine market, providing insights into both global and regional trends that are shaping prices. This report explores the spot price of zidovudine at major markets and analyzes the composition of prices, incorporating production and logistic costs. It presents in-depth zidovudine price trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Factors affecting zidovudine pricing, such as supply and demand dynamics, regulatory influences, and sectoral developments, are meticulously detailed. This comprehensive report aids stakeholders in staying informed with the latest market news, regulatory changes, and technological advancements, enabling informed strategic decision-making and forecasting.

The global zidovudine industry size reached USD 1.21 Billion in 2025. By 2034, IMARC Group expects the market to reach USD 1.81 Billion, at a projected CAGR of 4.42% during 2026-2034. Market growth is driven by sustained demand for antiretroviral therapies, expanding access to HIV treatment programs in emerging economies, increasing government-supported healthcare initiatives, and continued production of generic pharmaceutical formulations worldwide.
Zidovudine is a synthetic nucleoside analogue active pharmaceutical ingredient used mainly in antiretroviral medicines for HIV treatment. It belongs to the class of reverse transcriptase inhibitors and works by interfering with viral replication processes. The compound contains carbon, hydrogen, nitrogen, and oxygen elements arranged in a chemical structure designed to mimic natural nucleosides. Zidovudine is known for its pharmaceutical activity, stability, and compatibility with combination therapies. It is manufactured under strict quality standards to ensure purity and safety for medical applications. The product is primarily used by pharmaceutical companies producing antiviral formulations, including tablets, capsules, and other dosage forms. It plays an important role in global healthcare systems focused on managing HIV infections and improving patient treatment outcomes.
| Key Attributes | Details |
|---|---|
| Product Name | Zidovudine |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Zidovudine Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.